Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Long-term persistence of zoster vaccine efficacy.

Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN; Shingles Prevention Study Group..

Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918.

2.

Safety of zoster vaccine in elderly adults following documented herpes zoster.

Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, Neuzil KM, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group..

J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182.

3.

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; Shingles Prevention Study Group..

Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638.

4.

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults.

Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group..

J Am Geriatr Soc. 2010 Sep;58(9):1634-41. doi: 10.1111/j.1532-5415.2010.03021.x.

5.

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schödel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ; US Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators..

J Infect Dis. 2009 Oct 1;200(7):1068-77. doi: 10.1086/605611.

6.

A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Harbecke R, Oxman MN, Arnold BA, Ip C, Johnson GR, Levin MJ, Gelb LD, Schmader KE, Straus SE, Wang H, Wright PF, Pachucki CT, Gershon AA, Arbeit RD, Davis LE, Simberkoff MS, Weinberg A, Williams HM, Cheney C, Petrukhin L, Abraham KG, Shaw A, Manoff S, Antonello JM, Green T, Wang Y, Tan C, Keller PM; Shingles Prevention Study Group..

J Med Virol. 2009 Jul;81(7):1310-22. doi: 10.1002/jmv.21506.

7.

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators..

J Infect Dis. 2008 Mar 15;197(6):825-35. doi: 10.1086/528696.

8.

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL; Shingles Prevention Study Group..

N Engl J Med. 2005 Jun 2;352(22):2271-84.

9.

Repression of enzymes of the pentose phosphate pathway by glucose in fission yeast.

Mehta S, Velmurugan S, Lobo Z.

FEBS Lett. 1998 Dec 4;440(3):430-3.

10.

Std1, a gene involved in glucose transport in Schizosaccharomyces pombe.

Mehta SV, Patil VB, Velmurugan S, Lobo Z, Maitra PK.

J Bacteriol. 1998 Feb;180(3):674-9.

11.

Suppression of pdc2 regulating pyruvate decarboxylase synthesis in yeast.

Velmurugan S, Lobo Z, Maitra PK.

Genetics. 1997 Mar;145(3):587-94.

12.

Symptom control problems in an Indian hospice.

de Souza LJ, Lobo ZM.

Ann Acad Med Singapore. 1994 Mar;23(2):287-91.

PMID:
8080231
14.

Expression of the Escherichia coli xylose isomerase gene in Saccharomyces cerevisiae.

Sarthy AV, McConaughy BL, Lobo Z, Sundstrom JA, Furlong CE, Hall BD.

Appl Environ Microbiol. 1987 Sep;53(9):1996-2000.

15.

Saccharomyces cerevisiae aldolase mutants.

Lobo Z.

J Bacteriol. 1984 Oct;160(1):222-6.

16.

Mutations in the regulatory subunit of soluble phosphofructokinase from yeast.

Nadkarni M, Parmar L, Lobo Z, Maitra PK.

FEBS Lett. 1984 Oct 1;175(2):294-8.

17.

Multiple genes control particulate phosphofructokinase of yeast.

Parmar L, Lobo Z, Nadkarni M, Maitra PK.

Mol Gen Genet. 1984;197(3):515-6.

PMID:
6241288
18.

Genetics of yeast glucokinase.

Maitra PK, Lobo Z.

Genetics. 1983 Nov;105(3):501-15.

19.

Phosphofructokinase mutants of yeast. Biochemistry and genetics.

Lobo Z, Maitra PK.

J Biol Chem. 1983 Feb 10;258(3):1444-9.

20.

Particulate phosphofructokinase of yeast: physiological studies.

Nadkarni M, Lobo Z, Maitra PK.

FEBS Lett. 1982 Oct 18;147(2):251-5. No abstract available.

Supplemental Content

Loading ...
Support Center